Stryker Competitors

Abbott Laboratories (NYSE:ABT) and Stryker (NYSE:SYK) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.

Dividends

Abbott Laboratories pays an annual dividend of $1.80 per share and has a dividend yield of 1.5%. Stryker pays an annual dividend of $2.52 per share and has a dividend yield of 0.9%. Abbott Laboratories pays out 49.3% of its earnings in the form of a dividend. Stryker pays out 33.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Abbott Laboratories has increased its dividend for 49 consecutive years and Stryker has increased its dividend for 1 consecutive years. Abbott Laboratories is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Insider & Institutional Ownership

73.0% of Abbott Laboratories shares are held by institutional investors. Comparatively, 72.3% of Stryker shares are held by institutional investors. 1.5% of Abbott Laboratories shares are held by company insiders. Comparatively, 6.7% of Stryker shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Abbott Laboratories and Stryker's revenue, earnings per share (EPS) and valuation.

Abbott Laboratories has higher revenue and earnings than Stryker. Abbott Laboratories is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Abbott Laboratories and Stryker, as provided by MarketBeat.

Abbott Laboratories currently has a consensus target price of $124.6667, suggesting a potential upside of 2.62%. Stryker has a consensus target price of $283.8636, suggesting a potential upside of 3.99%. Given Stryker's higher probable upside, analysts clearly believe Stryker is more favorable than Abbott Laboratories.

Profitability

This table compares Abbott Laboratories and Stryker's net margins, return on equity and return on assets.

Risk and Volatility

Abbott Laboratories has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500. Comparatively, Stryker has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500.

Summary

Abbott Laboratories beats Stryker on 9 of the 17 factors compared between the two stocks.

Medtronic (NYSE:MDT) and Stryker (NYSE:SYK) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations and profitability.

Dividends

Medtronic pays an annual dividend of $2.52 per share and has a dividend yield of 1.9%. Stryker pays an annual dividend of $2.52 per share and has a dividend yield of 0.9%. Stryker pays out 33.9% of its earnings in the form of a dividend. Medtronic has raised its dividend for 44 consecutive years and Stryker has raised its dividend for 1 consecutive years. Medtronic is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Institutional & Insider Ownership

79.5% of Medtronic shares are owned by institutional investors. Comparatively, 72.3% of Stryker shares are owned by institutional investors. 0.5% of Medtronic shares are owned by company insiders. Comparatively, 6.7% of Stryker shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Medtronic and Stryker's top-line revenue, earnings per share and valuation.

Medtronic has higher revenue and earnings than Stryker.

Analyst Ratings

This is a summary of recent recommendations for Medtronic and Stryker, as provided by MarketBeat.

Medtronic currently has a consensus target price of $135.1364, suggesting a potential upside of 2.32%. Stryker has a consensus target price of $283.8636, suggesting a potential upside of 3.99%. Given Stryker's higher probable upside, analysts clearly believe Stryker is more favorable than Medtronic.

Profitability

This table compares Medtronic and Stryker's net margins, return on equity and return on assets.

Risk & Volatility

Medtronic has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500. Comparatively, Stryker has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500.

Intuitive Surgical (NASDAQ:ISRG) and Stryker (NYSE:SYK) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations and profitability.

Insider & Institutional Ownership

83.7% of Intuitive Surgical shares are owned by institutional investors. Comparatively, 72.3% of Stryker shares are owned by institutional investors. 0.9% of Intuitive Surgical shares are owned by company insiders. Comparatively, 6.7% of Stryker shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Intuitive Surgical and Stryker's revenue, earnings per share and valuation.

Stryker has higher revenue and earnings than Intuitive Surgical. Stryker is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations for Intuitive Surgical and Stryker, as provided by MarketBeat.

Intuitive Surgical currently has a consensus target price of $939.3529, suggesting a potential downside of 5.85%. Stryker has a consensus target price of $283.8636, suggesting a potential upside of 3.99%. Given Stryker's stronger consensus rating and higher probable upside, analysts clearly believe Stryker is more favorable than Intuitive Surgical.

Profitability

This table compares Intuitive Surgical and Stryker's net margins, return on equity and return on assets.

Risk & Volatility

Intuitive Surgical has a beta of 1.05, indicating that its stock price is 5% more volatile than the S&P 500. Comparatively, Stryker has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500.

Becton, Dickinson and (NYSE:BDX) and Stryker (NYSE:SYK) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations and profitability.

Analyst Ratings

This is a summary of recent recommendations for Becton, Dickinson and and Stryker, as provided by MarketBeat.

Becton, Dickinson and currently has a consensus target price of $276.75, suggesting a potential upside of 7.97%. Stryker has a consensus target price of $283.8636, suggesting a potential upside of 3.99%. Given Becton, Dickinson and's higher probable upside, equities research analysts clearly believe Becton, Dickinson and is more favorable than Stryker.

Profitability

This table compares Becton, Dickinson and and Stryker's net margins, return on equity and return on assets.

Institutional & Insider Ownership

83.3% of Becton, Dickinson and shares are owned by institutional investors. Comparatively, 72.3% of Stryker shares are owned by institutional investors. 0.8% of Becton, Dickinson and shares are owned by company insiders. Comparatively, 6.7% of Stryker shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Dividends

Becton, Dickinson and pays an annual dividend of $3.32 per share and has a dividend yield of 1.3%. Stryker pays an annual dividend of $2.52 per share and has a dividend yield of 0.9%. Becton, Dickinson and pays out 32.5% of its earnings in the form of a dividend. Stryker pays out 33.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Becton, Dickinson and has raised its dividend for 50 consecutive years and Stryker has raised its dividend for 1 consecutive years. Becton, Dickinson and is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Risk & Volatility

Becton, Dickinson and has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500. Comparatively, Stryker has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500.

Valuation & Earnings

This table compares Becton, Dickinson and and Stryker's top-line revenue, earnings per share and valuation.

Stryker has lower revenue, but higher earnings than Becton, Dickinson and. Becton, Dickinson and is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Summary

Stryker beats Becton, Dickinson and on 10 of the 17 factors compared between the two stocks.

Stryker (NYSE:SYK) and Edwards Lifesciences (NYSE:EW) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

Analyst Ratings

This is a breakdown of current ratings for Stryker and Edwards Lifesciences, as reported by MarketBeat.

Stryker currently has a consensus price target of $283.8636, suggesting a potential upside of 3.99%. Edwards Lifesciences has a consensus price target of $119.3333, suggesting a potential upside of 5.09%. Given Edwards Lifesciences' stronger consensus rating and higher probable upside, analysts plainly believe Edwards Lifesciences is more favorable than Stryker.

Profitability

This table compares Stryker and Edwards Lifesciences' net margins, return on equity and return on assets.

Institutional & Insider Ownership

72.3% of Stryker shares are owned by institutional investors. Comparatively, 80.3% of Edwards Lifesciences shares are owned by institutional investors. 6.7% of Stryker shares are owned by insiders. Comparatively, 1.4% of Edwards Lifesciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

Stryker has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500.

Valuation and Earnings

This table compares Stryker and Edwards Lifesciences' top-line revenue, earnings per share (EPS) and valuation.

Stryker has higher revenue and earnings than Edwards Lifesciences. Stryker is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Summary

Edwards Lifesciences beats Stryker on 8 of the 14 factors compared between the two stocks.

Stryker (NYSE:SYK) and Boston Scientific (NYSE:BSX) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

Analyst Ratings

This is a breakdown of current ratings for Stryker and Boston Scientific, as reported by MarketBeat.

Stryker currently has a consensus price target of $283.8636, suggesting a potential upside of 3.99%. Boston Scientific has a consensus price target of $48.91, suggesting a potential upside of 6.00%. Given Boston Scientific's stronger consensus rating and higher probable upside, analysts plainly believe Boston Scientific is more favorable than Stryker.

Profitability

This table compares Stryker and Boston Scientific's net margins, return on equity and return on assets.

Institutional & Insider Ownership

72.3% of Stryker shares are owned by institutional investors. Comparatively, 89.6% of Boston Scientific shares are owned by institutional investors. 6.7% of Stryker shares are owned by insiders. Comparatively, 0.7% of Boston Scientific shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

Stryker has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500. Comparatively, Boston Scientific has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500.

Valuation and Earnings

This table compares Stryker and Boston Scientific's top-line revenue, earnings per share (EPS) and valuation.

Stryker has higher revenue and earnings than Boston Scientific. Stryker is trading at a lower price-to-earnings ratio than Boston Scientific, indicating that it is currently the more affordable of the two stocks.

Summary

Stryker beats Boston Scientific on 10 of the 15 factors compared between the two stocks.